JP2022504075A - 操作された遺伝子モジュレーター - Google Patents
操作された遺伝子モジュレーター Download PDFInfo
- Publication number
- JP2022504075A JP2022504075A JP2021518086A JP2021518086A JP2022504075A JP 2022504075 A JP2022504075 A JP 2022504075A JP 2021518086 A JP2021518086 A JP 2021518086A JP 2021518086 A JP2021518086 A JP 2021518086A JP 2022504075 A JP2022504075 A JP 2022504075A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- zfp
- target
- domain
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 384
- 230000014509 gene expression Effects 0.000 claims abstract description 173
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 122
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 122
- 210000004027 cell Anatomy 0.000 claims description 187
- 101710185494 Zinc finger protein Proteins 0.000 claims description 124
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims description 121
- 239000000203 mixture Substances 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 112
- 108010026424 tau Proteins Proteins 0.000 claims description 103
- 239000013598 vector Substances 0.000 claims description 102
- 108020004999 messenger RNA Proteins 0.000 claims description 94
- 230000002195 synergetic effect Effects 0.000 claims description 94
- 230000004568 DNA-binding Effects 0.000 claims description 92
- 108091033409 CRISPR Proteins 0.000 claims description 79
- 230000001629 suppression Effects 0.000 claims description 72
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 51
- 101710163270 Nuclease Proteins 0.000 claims description 48
- 239000002773 nucleotide Substances 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 238000010354 CRISPR gene editing Methods 0.000 claims description 47
- 102000040430 polynucleotide Human genes 0.000 claims description 43
- 108091033319 polynucleotide Proteins 0.000 claims description 43
- 239000002157 polynucleotide Substances 0.000 claims description 43
- 210000004556 brain Anatomy 0.000 claims description 39
- 210000002569 neuron Anatomy 0.000 claims description 28
- 238000001727 in vivo Methods 0.000 claims description 24
- 230000001105 regulatory effect Effects 0.000 claims description 24
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000013603 viral vector Substances 0.000 claims description 21
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims description 17
- 108091000054 Prion Proteins 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 14
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 claims description 13
- 241000702421 Dependoparvovirus Species 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 102000003964 Histone deacetylase Human genes 0.000 claims description 11
- 108090000353 Histone deacetylase Proteins 0.000 claims description 11
- 102000029797 Prion Human genes 0.000 claims description 11
- 230000010354 integration Effects 0.000 claims description 11
- 208000034799 Tauopathies Diseases 0.000 claims description 10
- 230000002776 aggregation Effects 0.000 claims description 10
- 238000004220 aggregation Methods 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 210000001320 hippocampus Anatomy 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 8
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 8
- 108010033040 Histones Proteins 0.000 claims description 8
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 claims description 8
- 201000002832 Lewy body dementia Diseases 0.000 claims description 8
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 210000001577 neostriatum Anatomy 0.000 claims description 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 101150014718 C9orf72 gene Proteins 0.000 claims description 6
- 102100024811 DNA (cytosine-5)-methyltransferase 3-like Human genes 0.000 claims description 6
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 6
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 6
- 101000909250 Homo sapiens DNA (cytosine-5)-methyltransferase 3-like Proteins 0.000 claims description 6
- 208000024777 Prion disease Diseases 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 210000001353 entorhinal cortex Anatomy 0.000 claims description 6
- 238000007917 intracranial administration Methods 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 238000007913 intrathecal administration Methods 0.000 claims description 6
- 230000037426 transcriptional repression Effects 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 5
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 claims description 5
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 claims description 5
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 claims description 5
- 101150043003 Htt gene Proteins 0.000 claims description 5
- 101150070547 MAPT gene Proteins 0.000 claims description 5
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims description 5
- 230000000971 hippocampal effect Effects 0.000 claims description 5
- 238000007914 intraventricular administration Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 210000002241 neurite Anatomy 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 210000005153 frontal cortex Anatomy 0.000 claims description 4
- 230000001988 toxicity Effects 0.000 claims description 4
- 231100000419 toxicity Toxicity 0.000 claims description 4
- 101150029341 ATXN2 gene Proteins 0.000 claims description 3
- 101150074725 Atxn3 gene Proteins 0.000 claims description 3
- 101150032457 CDKL5 gene Proteins 0.000 claims description 3
- 101150054841 DUX4 gene Proteins 0.000 claims description 3
- 101150082209 Fmr1 gene Proteins 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 108010036115 Histone Methyltransferases Proteins 0.000 claims description 3
- 102000011787 Histone Methyltransferases Human genes 0.000 claims description 3
- 101100164975 Homo sapiens ATXN2 gene Proteins 0.000 claims description 3
- 101100439048 Homo sapiens CDKL5 gene Proteins 0.000 claims description 3
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 101150083522 MECP2 gene Proteins 0.000 claims description 3
- 206010029350 Neurotoxicity Diseases 0.000 claims description 3
- 101710114165 Progranulin Proteins 0.000 claims description 3
- 101150110423 SNCA gene Proteins 0.000 claims description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 3
- 108091060203 Ube3a-ATS Proteins 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 239000000090 biomarker Substances 0.000 claims description 3
- 210000000133 brain stem Anatomy 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 230000001819 effect on gene Effects 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 230000007135 neurotoxicity Effects 0.000 claims description 3
- 231100000228 neurotoxicity Toxicity 0.000 claims description 3
- 230000001936 parietal effect Effects 0.000 claims description 3
- 239000011885 synergistic combination Substances 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 101150057301 PRP gene Proteins 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000002964 excitative effect Effects 0.000 claims description 2
- 210000003478 temporal lobe Anatomy 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 102100037632 Progranulin Human genes 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 109
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 109
- 102000004169 proteins and genes Human genes 0.000 description 98
- 102000013498 tau Proteins Human genes 0.000 description 95
- 235000018102 proteins Nutrition 0.000 description 93
- 150000007523 nucleic acids Chemical class 0.000 description 61
- 102000039446 nucleic acids Human genes 0.000 description 59
- 108020004707 nucleic acids Proteins 0.000 description 59
- 108020004414 DNA Proteins 0.000 description 44
- 238000003776 cleavage reaction Methods 0.000 description 44
- 230000007017 scission Effects 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 230000004927 fusion Effects 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 33
- 238000001890 transfection Methods 0.000 description 29
- 230000027455 binding Effects 0.000 description 28
- 239000013607 AAV vector Substances 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 25
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 23
- 208000023105 Huntington disease Diseases 0.000 description 22
- 108020001507 fusion proteins Proteins 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 20
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 19
- 239000011701 zinc Substances 0.000 description 19
- 229910052725 zinc Inorganic materials 0.000 description 19
- 208000024827 Alzheimer disease Diseases 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- -1 TALE-TF Proteins 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 238000001415 gene therapy Methods 0.000 description 15
- 102000001435 Synapsin Human genes 0.000 description 14
- 108050009621 Synapsin Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 241000701161 unidentified adenovirus Species 0.000 description 14
- 238000010459 TALEN Methods 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000002103 transcriptional effect Effects 0.000 description 12
- 108020005004 Guide RNA Proteins 0.000 description 11
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 11
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 108091028113 Trans-activating crRNA Proteins 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 102000004533 Endonucleases Human genes 0.000 description 9
- 108010042407 Endonucleases Proteins 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 7
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 210000003483 chromatin Anatomy 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000001052 transient effect Effects 0.000 description 7
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 101000915539 Homo sapiens Zinc finger protein 1 homolog Proteins 0.000 description 6
- 102100028610 Zinc finger protein 1 homolog Human genes 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 description 5
- 101710096438 DNA-binding protein Proteins 0.000 description 5
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 description 5
- 101000915531 Homo sapiens Zinc finger protein ZFP2 Proteins 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- 241000589634 Xanthomonas Species 0.000 description 5
- 102100028612 Zinc finger protein ZFP2 Human genes 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102100034452 Alternative prion protein Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 description 4
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100298534 Mus musculus Prnp gene Proteins 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000009437 off-target effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101500023984 Drosophila melanogaster Synapsin-1 Proteins 0.000 description 3
- 102100022462 Eukaryotic initiation factor 4A-II Human genes 0.000 description 3
- 101000959666 Homo sapiens Eukaryotic initiation factor 4A-I Proteins 0.000 description 3
- 101001044475 Homo sapiens Eukaryotic initiation factor 4A-II Proteins 0.000 description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108700019961 Neoplasm Genes Proteins 0.000 description 3
- 102000048850 Neoplasm Genes Human genes 0.000 description 3
- 101150044568 PRNP gene Proteins 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 108050002485 Sirtuin Proteins 0.000 description 3
- 102000011990 Sirtuin Human genes 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 101001030716 Arabidopsis thaliana Histone deacetylase HDT1 Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108700030955 C9orf72 Proteins 0.000 description 2
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 2
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 2
- 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 2
- 101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000860092 Francisella tularensis subsp. novicida (strain U112) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 2
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700040121 Protein Methyltransferases Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 2
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 2
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 101100087805 Ralstonia solanacearum rip19 gene Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000032859 Synucleinopathies Diseases 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000006277 exogenous ligand Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QXSIYYQGSPCIHN-UHFFFAOYSA-N 1,1-dimethyl-2-[4-(5-nitrofuran-2-yl)-1,3-thiazol-2-yl]hydrazine Chemical compound S1C(NN(C)C)=NC(C=2OC(=CC=2)[N+]([O-])=O)=C1 QXSIYYQGSPCIHN-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102100030982 60S ribosomal protein L38 Human genes 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 101150084229 ATXN1 gene Proteins 0.000 description 1
- 101150072286 ATXN7 gene Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100029582 DDB1- and CUL4-associated factor 1 Human genes 0.000 description 1
- 101710155335 DELLA protein SLR1 Proteins 0.000 description 1
- LUKZREJJLWEWQM-UHFFFAOYSA-N DMNT Natural products CC(C)=CCCC(C)=CC=C LUKZREJJLWEWQM-UHFFFAOYSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 101100049549 Enterobacteria phage P4 sid gene Proteins 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 1
- 102000041143 GNAT family Human genes 0.000 description 1
- 108091061015 GNAT family Proteins 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 1
- 101710116149 Histone acetyltransferase KAT5 Proteins 0.000 description 1
- 102100033069 Histone acetyltransferase KAT8 Human genes 0.000 description 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 1
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 description 1
- 108050002855 Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 102100023696 Histone-lysine N-methyltransferase SETDB1 Human genes 0.000 description 1
- 101001127039 Homo sapiens 60S ribosomal protein L38 Proteins 0.000 description 1
- 101100164990 Homo sapiens ATXN7 gene Proteins 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101000917426 Homo sapiens DDB1- and CUL4-associated factor 1 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101000944170 Homo sapiens Histone acetyltransferase KAT8 Proteins 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 101000684609 Homo sapiens Histone-lysine N-methyltransferase SETDB1 Proteins 0.000 description 1
- 101000615495 Homo sapiens Methyl-CpG-binding domain protein 3 Proteins 0.000 description 1
- 101100435109 Homo sapiens PRNP gene Proteins 0.000 description 1
- 101000757232 Homo sapiens Protein arginine N-methyltransferase 2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000945093 Homo sapiens Ribosomal protein S6 kinase alpha-4 Proteins 0.000 description 1
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 1
- 101000971144 Homo sapiens Tyrosine-protein kinase BAZ1B Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 101100341791 Mus musculus Kat2b gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102100027771 N-lysine methyltransferase KMT5A Human genes 0.000 description 1
- 101710117516 N-lysine methyltransferase KMT5A Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100063942 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) dot-1 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101100046877 Oryza sativa subsp. japonica TRAB1 gene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 101100440941 Petroselinum crispum CPRF1 gene Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100022988 Protein arginine N-methyltransferase 2 Human genes 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101150065817 ROM2 gene Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- 101100272715 Ralstonia solanacearum (strain GMI1000) brg11 gene Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100033644 Ribosomal protein S6 kinase alpha-4 Human genes 0.000 description 1
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 101100421299 Schizosaccharomyces pombe (strain 972 / ATCC 24843) set7 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 101150117538 Set2 gene Proteins 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 241001162933 Therophilus Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100021575 Tyrosine-protein kinase BAZ1B Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000026925 anterograde axon cargo transport Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000000005 bacterial plant pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 102000045354 human SNCA Human genes 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000021127 protein binding proteins Human genes 0.000 description 1
- 108091011138 protein binding proteins Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 101150079354 rho gene Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2018年10月2日に出願された米国仮特許出願第62/740,156号の利益を請求し、その開示はその全体が参照により本明細書に組み込まれる。
することができる。例えば、本明細書に記載のリプレッサーを使用して、タウオパチー(例えば、AD)またはHDを有する対象の脳におけるタウまたは突然変異Httの凝集を低減させるか、または除去し、疾患の症状を低減させることができる。
本明細書に開示される方法の実施、ならびに組成物の調製および使用は、別途指摘しない限り、分子生物学、生化学、クロマチンの構造および分析、コンピュータ化学、細胞培養、組換えDNAおよび当業者の知識の範囲内にある関連分野における従来の技術を用いる。これらの技術は、文献中で完全に説明されている。例えば、Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989およびThird edition, 2001;Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987およびその定期的アップデート;the series METHODS IN ENZYMOLOGY, Academic Press, San Diego;Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998;METHODS IN ENZYMOLOGY, Vol. 304, “Chromatin” (P.M. Wassarman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999;ならびにMETHODS IN MOLECULAR BIOLOGY, Vol. 119, “Chromatin Protocols” (P.B. Becker, ed.) Humana Press, Totowa, 1999を参照されたい。
用語「核酸」、「ポリヌクレオチド」および「オリゴヌクレオチド」は、互換的に使用され、線状または環状コンフォメーションの、一本鎖または二本鎖形態にあるデオキシリボヌクレオチドまたはリボヌクレオチドポリマーを指す。本開示の目的のために、これらの用語は、ポリマーの長さに関する限定と解釈されるべきではない。この用語は、天然ヌクレオチドの公知のアナログ、ならびに塩基、糖および/またはリン酸部分(例えば、ホスホロチオエート骨格)において修飾されたヌクレオチドを包含してもよい。一般に、特定のヌクレオチドのアナログは、同じ塩基対形成特異性を有する;すなわち、Aのアナログは、Tと塩基対を形成するであろう。
本明細書に記載の遺伝子モジュレーターは、それぞれの人工転写因子(TF)がDNA結合ドメインと、1つまたは複数の機能ドメインとを含む、2つ以上の人工転写因子(例えば、リプレッサーまたは活性化因子)を含む。本明細書に記載の遺伝子モジュレーターは、特異性(オフターゲット遺伝子のモジュレーションを限定する、もしくは除去する)および/または活性(モジュレーションの量)に対する相乗効果を含む、単一の転写因子と比較して相乗効果を示す。かくして、相乗効果は、個々のTF(および/または予想される相加効果)と比較して、約1倍、約2倍、約3倍、約4倍、約5倍、約6倍、約7倍、約8倍を超える、またはそれ以上の活性および/または特異性の任意の増加である。
任意のポリヌクレオチドまたはポリペプチドDNA結合ドメイン、例えば、DNA結合タンパク質(例えば、ZFPもしくはTALE)またはDNA結合ポリヌクレオチド(例えば、単一ガイドRNA)を、本明細書に開示される組成物および方法において使用することができる。遺伝子モジュレーターのDNA結合ドメインを、疾患または障害において異常に発現される1つまたは複数の遺伝子などの、目的の任意の遺伝子に標的化することができる。DNA結合ドメインによって認識される2つ以上の標的部位は、重複していても、または重複していなくてもよい。2つのDNA結合ドメインのための標的部位は、最大で約600塩基対以上隔てられていてもよく、標的遺伝子の転写開始部位(いずれかの側の)から最大で300塩基対以上であってもよい。さらに、内因性ゲノムなどの二本鎖DNAを標的化する場合、人工転写因子のDNA結合ドメインは、同じか、または異なる鎖を(1つもしくは複数がプラス鎖を、および/または1つもしくは複数がマイナス鎖を)標的としてもよい。さらに、同じか、または異なるDNA結合ドメインを、本発明の遺伝子モジュレーター中で使用することができる。かくして、任意の遺伝子の遺伝子モジュレーター(リプレッサー)が記載される。
種 PAM
S.pyogenes NGG
S.pyogenes NAG
S.mutans NGG
S.thermophilius NGGNG
S.thermophilius NNAAAW
S.thermophilius NNAGAA
S.thermophilius NNNGATT
C.jejuni NNNNACA
N.meningitides NNNGATT
P.multocida GNNNCNNA
F.novicida NG
DNA結合ドメインを、1つまたは複数の機能ドメインに融合するか、またはそうでなければそれと結合して、本明細書に記載の人工転写因子を形成させることができる。ある特定の実施形態では、方法は、少なくとも1つのDNA結合分子(例えば、ZFP、TALEまたは単一ガイドRNA)と、異種調節(機能)ドメイン(またはその機能的断片)とを含む融合分子を用いる。
タンパク質および/またはポリヌクレオチド(例えば、遺伝子モジュレーター)ならびに本明細書に記載のタンパク質および/またはポリヌクレオチドを含む組成物を、例えば、mRNAによるタンパク質の注入および/または発現コンストラクト(例えば、プラスミド、レンチウイルスベクター、AAVベクター、Adベクターなど)の使用などの、任意の好適な手段によって、標的細胞に送達することができる。好ましい実施形態では、リプレッサーは、限定されるものではないが、AAV2/6またはAAV2/9(米国特許第7,198,951号を参照されたい)、米国特許第9,585,971号に記載のAAVベクターなどの、AAVベクターを使用して送達される。
CNS障害の試験を、非ヒト霊長類(例えば、パーキンソン病(Johnston and Fox (2015) Curr Top Behav Neurosci 22: 221-35);筋萎縮性側索硬化症(Jackson et al., (2015) J. Med Primatol: 44(2):66-75)、ハンチントン病(Yang et al., (2008) Nature 453(7197):921-4);アルツハイマー病(Park et al., (2015) Int J Mol Sci 16(2):2386-402);発作(Hsiao et al., (2016) E Bio Med 9:257-77))、イヌ科(例えば、MPS VII(Gurda et al., (2016) Mol Ther 24(2):206-216);アルツハイマー病(Schutt et al., (2016) J Alzheimers Dis 52(2):433-49);発作(Varatharajah et al., (2017) Int J Neural Syst 27(1):1650046))およびマウス(例えば、発作(Kadiyala et al., (2015) Epilepsy Res 109:183-96);アルツハイマー病(Li et al., (2015) J Alzheimers Dis Parkin 5(3) doi 10:4172/2161-0460))などの動物モデル系において実行することができる(概説:Webster et al., (2014) Front Genet 5 art 88, doi:10.3389f/gene.2014.00088)。これらのモデルは疾患の特定の症状セットを精査するのに有用であり得るため、CNS疾患を完全に再現する動物モデルが存在しない場合であっても、これらのモデルを使用することができる。このモデルは、本明細書に記載の治療方法および組成物(遺伝子リプレッサー)の効能および安全性プロファイルを決定するのに役立ち得る。
複数の人工転写因子を含む本明細書に記載の遺伝子モジュレーター(例えば、リプレッサー)を、遺伝子発現の特異的モジュレーションが望まれる任意の適用のために使用することができる。これらの適用は、少なくとも1つの遺伝子モジュレーターが、ウイルス(例えば、AAV)または非ウイルスベクターを使用して対象に投与され、対象内での標的遺伝子の発現をモジュレートするために使用される治療方法を含む。モジュレーションは、抑制、例えば、疾患状態に寄与している遺伝子発現(例えば、HDにおいてはHtt、ALSにおいては突然変異C9ORF72、PDおよびDLBにおいてはSNCA、ADにおいてはタウ、プリオン病においてはPRNP)の抑制の形態にあってもよい。あるいは、モジュレーションは、内因性細胞遺伝子の発現の活性化または発現の増加が疾患状態を改善することができる場合、活性化の形態にあってもよい。上述の通り、そのような適用のために、本明細書に記載の遺伝子モジュレーターをコードする核酸は、医薬組成物として薬学的に許容される担体と共に製剤化される。
相乗的ZFP-TFリプレッサー
相乗的ZFP-TFリプレッサーを含む組成物を、ZFP-TFのパネルを、個別に、および様々な組合せでスクリーニングすることによって同定した。
約185個の亜鉛フィンガータンパク質のスクリーニングを、米国特許出願公開第20180153921号に記載のように行った。ZFPと抑制ドメインとを含むZFP-TFも試験し、発現を抑制することを見出した。さらに、個々のZFPによる抑制を、組み合わせ、試験した様々な対と比較した。
また、マウスPrnp遺伝子に標的化されたZFP-TFを、本質的には上記のように、相乗効果についてスクリーニングした。簡単に述べると、32個の異なる個々のZFP-TFおよび130個の異なるこれらのZFP-TFの対合した組合せをコードする3つの異なる用量(個々のZFP-TFについては200、60、20ngおよび対合した組合せについては100、30および10ng)のmRNAを、Neuro2A細胞にトランスフェクトした。24時間後、全RNAを抽出し、Prnpおよび2つの参照遺伝子(ATP5b、EIF4A)の発現を、リアルタイムRT-qPCRを使用してモニタリングした。組合せ中でその用量の2倍で試験した場合のより強力なZFPについて得られた発現レベルの、ZFP組合せについて得られたものに対する比として、相乗効果を算出した。
また、ヒトPRNP遺伝子に標的化されたZFP-TFを、本質的には上記のように、相乗効果についてスクリーニングした。簡単に述べると、32個の異なる個々のZFP-TFおよび130個の異なるこれらのZFP-TFの対合した組合せをコードする3つの異なる用量(個々のZFP-TFについては200、60、20ngおよび対合した組合せについては100、30および10ng)のmRNAを、SK-N-MC細胞にトランスフェクトした。24時間後、全RNAを抽出し、PRNPおよび2つの参照遺伝子(ATP5b、EIF4A)の発現を、リアルタイムRT-qPCRを使用してモニタリングした。組合せ中でその用量の2倍で試験した場合のより強力なZFPについて得られた発現レベルの、ZFP組合せについて得られた発現レベルに対する比として、相乗効果を算出した。
また、ヒトSNCAに標的化されたZFP-TFを、本質的には上記のように、相乗効果についてスクリーニングした。簡単に述べると、30個の異なる個々のZFP-TFおよび132個の異なるこれらのZFP-TFの対合した組合せをコードする3つの異なる用量(個々のZFP-TFについては200、60、20ngおよび対合した組合せについては100、30および10ng)のmRNAを、SK-N-MC細胞にトランスフェクトした。24時間後、全RNAを抽出し、SNCAおよび2つの参照遺伝子(ATP5b、EIF4A)の発現を、リアルタイムRT-qPCRを使用してモニタリングした。組合せ中でその用量の2倍で試験した場合のより強力なZFPについて得られた発現レベルの、ZFP組合せについて得られたものに対する比として、相乗効果を算出した。
オフターゲット効果
また、オフターゲット効果を、以下のように分析した。第1に、実施例1で同定された52335と52389との対を、全体マイクロアレイプロファイリングにおいて使用した。簡単に述べると、約300ngのそれぞれのZFP-TFをコードするmRNAを、個別に、または組み合わせて、生物学的4回反復において150kのNeuro2A細胞中にトランスフェクトした。約24時間後、全RNAを抽出し、製造業者のプロトコール(Affymetrix Genechip MTA1.0)によって処理した。ロバストなマルチアレイ平均(RMA)を使用して、それぞれのプローブセットに由来する生のシグナルを正規化した。「Gene Level Differential Expression Analysis」オプションを用いるTranscriptome Analysis Console 3.0(Affymetrix)を使用して、分析を実施した。ZFPをトランスフェクトした試料を、無関係のZFP-TF(MAPT標的部位に結合しない)で処理した試料と比較した。対照と比較した平均シグナルの2倍を超える差異、および0.05未満のP値(それぞれのプローブセットに関する一元配置分散分析、対応のないT検定)を示す転写物(プローブセット)についてチェンジコールを報告した。
デリバリー
多シストロン性デリバリーおよびコドン多様化された抑制ドメインも以下のように分析した。単一のZFP-TF(非連結)または複数の人工転写因子(自己切断性ペプチド配列、T2AおよびP2Aによって隔てられている)を運ぶ1つのmRNAと共に多シストロン性(連結)としてコードするmRNAを生成した。さらに、ZFP-TFは、Kox抑制ドメインの野生型またはコドン多様化された変異体(それぞれ、連結された構造内のN末端、中央、またはC末端位置について、nKox、mKox、およびcKoxと指定)を含み、デリバリーベクター中の反復配列を回避した。
インビボでの非ヒト霊長類試験
本明細書に記載の遺伝子リプレッサーを、カニクイザル(M.fascicularis)において試験して、霊長類(非ヒト霊長類(NHP)モデル)におけるタウ発現の抑制を観察した。カニクイザルを、自動給水系を装備したステンレススチール製のケージ中で飼育した。試験は、Final Rules of the Animal Welfare Act規則(Code of Federal Regulations、Title 9)およびGuide for the Care and Use of Laboratory Animals、Institute of Laboratory Animal Resources、Commission on Life Sciences、National Research Council、8th editionの全ての適用可能なセクションを順守した。
ヒトiPSニューロン中でのZFP-TFの活性
AAV2/6を使用して、約1E5 VG/細胞(iCell Neurons、Cellular Dynamics International Inc.)でヒトiPS由来ニューロンに感染させた。約19日後、全RNAを抽出し、ヒトMAPT、ZFP-KRAB、および3つの参照遺伝子(ATP5b、EIF4a2、GAPDH)の発現を、リアルタイムRT-qPCRを使用して評価した。
Claims (26)
- 2つ以上の人工転写因子を含む組成物であって、それぞれの人工転写因子が、DNA結合ドメインと機能ドメインとを含み、人工転写因子が細胞中の遺伝子発現を相乗的にモジュレートする、組成物。
- 細胞が単離されているか、または生きている対象中にある、請求項1に記載の組成物。
- HD、プリオン病、パーキンソン病、レヴィー小体型認知症(DLB)、筋萎縮性側索硬化症(ALS)、および/またはタウオパチーである疾患または障害のエクスビボまたはインビボでの処置における使用のための、請求項1または2に記載の組成物。
- 相乗的モジュレーションが個々の転写因子と比較して少なくとも約2倍である、請求項1から3のいずれか一項に記載の組成物。
- それぞれの人工転写因子が、12ヌクレオチド以上の標的部位に結合するDNA結合ドメインを含む、請求項1から4のいずれか一項に記載の組成物。
- それぞれの転写因子のDNA結合ドメインが、亜鉛フィンガータンパク質(ZFP)、TAL-エフェクタードメイン、および/またはCRISPR/Cas系のsgRNAを含む、請求項1から5のいずれか一項に記載の組成物。
- 機能ドメインが、転写活性化ドメイン、転写抑制ドメイン、DNMT1、DNMT3A、DNMT3B、DNMT3LなどのDNMTタンパク質、ヒストンデアセチラーゼ(HDAC)、ヒストンアセチルトランスフェラーゼ(HAT)、ヒストンメチラーゼ、またはヒストンをSUMO化もしくはビオチン化する酵素に由来するドメインおよび/または翻訳後ヒストン修飾により調節される遺伝子抑制を可能にする他の酵素ドメインを含む、請求項1から6のいずれか一項に記載の組成物。
- 2つ以上の人工転写因子が、
(i)選択された標的遺伝子中の少なくとも12ヌクレオチドの任意の標的部位に結合し、適宜、人工転写因子のうちの2つ以上が、同じ、異なる、および/もしくは重複する標的部位に結合する;
(ii)互いに10,000塩基対以上以内にある標的部位に結合する;
(iii)モジュレートしようとする標的遺伝子の転写開始部位(TSS)のいずれかの側の0~300塩基対以内にある標的部位に結合する;ならびに/または
(iv)二本鎖標的中のセンスおよび/もしくはアンチセンス鎖に結合する、
請求項1から7のいずれか一項に記載の組成物。 - 標的遺伝子が、タウ(MAPT)遺伝子、Htt遺伝子、突然変異Htt遺伝子、突然変異C9orf72遺伝子、SNCA遺伝子、プリオン遺伝子、SMA遺伝子、ATXN2遺伝子、ATXN3遺伝子、PRP遺伝子、Ube3a-ATSコード遺伝子、DUX4遺伝子、PGRN遺伝子、MECP2遺伝子、FMR1遺伝子、CDKL5遺伝子、またはLRKK2遺伝子である、請求項1から8のいずれか一項に記載の組成物。
- 2つ以上の人工転写因子が、遺伝子リプレッサー、適宜、野生型発現レベルと比較して、および/または単一の人工転写因子を使用した場合の発現レベルと比較して、標的遺伝子の発現を少なくとも50%~100%(またはその間の任意の値)抑制するリプレッサーである、請求項1から9のいずれか一項に記載の組成物。
- 2つ以上の人工転写因子が、遺伝子活性化因子、適宜、野生型発現レベルと比較して、および/または遺伝子が単一の遺伝子モジュレーターによってモジュレートされる場合の発現レベルと比較して、標的遺伝子の発現を1~5倍以上活性化する活性化因子である、請求項1から10のいずれか一項に記載の組成物。
- 機能ドメインの活性が、細胞の転写機構との相互作用が外因性リガンドの存在下では起こらないように、外因性低分子またはリガンドによって調節される、請求項1から11のいずれか一項に記載の組成物。
- 請求項1から12のいずれか一項に記載の組成物を含む医薬組成物。
- 人工転写因子が、1つまたは複数のポリヌクレオチドを使用して、適宜、1つまたは複数の人工転写因子をコードする配列を運ぶ1つまたは複数のウイルスまたは非ウイルスベクターを使用して、対象に提供され、ウイルスベクターが、アデノウイルスベクター、レンチウイルスベクター(LV)および/またはアデノ随伴ウイルスベクター(AAV)を含んでもよく、非ウイルスベクターがプラスミドおよび/または単もしくは多シストロン性mRNAを含んでもよい、請求項1から13のいずれか一項に記載の組成物。
- 対象の脳内で約4週間、約3カ月、約6カ月~約1年以上の期間にわたって遺伝子発現を低減させることによって、適宜、前頭前野皮質などの前頭葉皮質、頭頂葉皮質、後頭葉皮質;内嗅皮質などの側頭葉皮質、海馬、脳幹、線条体、視床、中脳、小脳ならびに/または脊髄の腰部、胸部および/もしくは頸部領域などの脊髄を含む、対象の脳に組成物を投与することによって、MAPT遺伝子発現を抑制することによってタウオパチーなどのCNS疾患もしくは障害を処置する;プリオンを抑制することによってプリオン病を処置する;α-シヌクレインを抑制することによってパーキンソン病を処置する;突然変異C9orf72遺伝子発現を抑制することによってALSを処置する;mHtt遺伝子発現を抑制することによってHDを処置する、請求項1から14のいずれか一項に記載の組成物。
- 静脈内、筋肉内、脳室内、髄腔内、頭蓋内、粘膜、経口、静脈内、眼窩(眼窩後方(RO))および/または嚢内投与によって対象に投与される、請求項1から15のいずれか一項に記載の組成物。
- (i)約10,000~100,000、もしくは約100,000~250,000、もしくは約250,000~500,000ベクターゲノム(VG)/細胞の用量、適宜、約1E11~1E14 VG/mLで脳実質に約1~300μLの固定容量で、および/もしくは約1E11~1E14 VG/mLでCSFに約0.5~10mLの固定容量で送達される、約10,000~500,000ベクターゲノム/細胞のアデノ随伴ウイルス(AAV)ベクター;
(ii)約250~1,000のMOIのレンチウイルスベクター;
(iii)約0.01~1,000ng/100,000細胞のプラスミドベクター;ならびに/または
(iv)約0.01~3000ng/100,000細胞のmRNA
を使用して送達される、請求項1から16のいずれか一項に記載の組成物。 - 遺伝子発現が、本明細書に記載の遺伝子モジュレーターを受けていない対照と比較して、細胞中で少なくとも30%、または40%、好ましくは少なくとも50%、さらにより好ましくは少なくとも70%、または少なくとも80%、または90%、または90%を超えて減少する、請求項1から17のいずれか一項に記載の組成物。
- 細胞が、ニューロンであり、HDまたはADニューロンであってもよい、請求項1から18のいずれか一項に記載の組成物。
- 1回投与されるか、または複数回投与される、請求項1から19のいずれか一項に記載の組成物。
- 疾患または障害のバイオマーカー、病原性種および/または症状を低減させるのに使用するためのものであり、神経毒性、グリオーシス、神経突起変性、脊椎喪失、興奮毒性、皮質および海馬の縮小、樹状タウ蓄積、認知障害、運動障害、アミロイドβ斑と関連する神経突起変性、タウ病原性種、mHtt凝集体、高リン酸化タウ、可溶性タウ、粒状タウ、タウ凝集、および/または神経原線維変化(NFT)が低減されてもよい、請求項1から20のいずれか一項に記載の組成物。
- 1つもしくは複数の人工転写因子をコードする配列が、ゲノム中に安定に組み込まれる、および/または人工転写因子をコードする1つもしくは複数の配列が、エピソームに保持され、安定な組込みがヌクレアーゼによって媒介される標的化された組込みであってよい、請求項1から21のいずれか一項に記載の組成物を含む細胞。
- 試薬および/または使用のための使用説明書をさらに含んでもよい、請求項1から22のいずれか一項に記載の1つもしくは複数の組成物および/または1つもしくは複数の細胞を含むキット。
- 請求項1から23のいずれか一項に期待の相乗的人工転写因子を含む組成物を作製する方法であって、
選択された遺伝子に標的化される、個々の2つ以上の人工転写因子およびその組合せを、遺伝子発現に対するその効果についてスクリーニングすること;ならびに
人工ZFP-TFの相乗的組合せを同定すること
を含む方法。 - 2つ以上の人工転写因子が、
(i)1~600塩基対離れている、標的部位に結合する、および/もしくは機能ドメインを含む;
(ii)約1~80;160~220;260~400;もしくは500~600塩基対離れている標的部位に結合する;
(iii)互いに約1~80;260~400;もしくは500~600塩基対隔てられている機能ドメインを含む;
(iv)転写開始部位(TSS)のいずれかの側の約400塩基対以内にある標的部位に結合する;ならびに/または
(v)同じアンチセンス(-)もしくはセンス(+)鎖、またはいずれかの配向の異なる鎖に結合する、
請求項24に記載の方法。 - 相乗的人工TFが、個々のTFよりも標的遺伝子のモジュレーションにおいて少なくとも2倍活性が高い、請求項24または25に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862740156P | 2018-10-02 | 2018-10-02 | |
US62/740,156 | 2018-10-02 | ||
PCT/US2019/054347 WO2020072684A1 (en) | 2018-10-02 | 2019-10-02 | Engineered genetic modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022504075A true JP2022504075A (ja) | 2022-01-13 |
Family
ID=70051837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518086A Pending JP2022504075A (ja) | 2018-10-02 | 2019-10-02 | 操作された遺伝子モジュレーター |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200109406A1 (ja) |
EP (1) | EP3861130A4 (ja) |
JP (1) | JP2022504075A (ja) |
KR (1) | KR20210069692A (ja) |
CN (1) | CN113195002A (ja) |
AU (1) | AU2019354743A1 (ja) |
CA (1) | CA3115158A1 (ja) |
IL (1) | IL281950A (ja) |
SG (1) | SG11202103314QA (ja) |
WO (1) | WO2020072684A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
ES2929110T3 (es) | 2015-08-25 | 2022-11-24 | Univ Duke | Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
AU2017367722B2 (en) | 2016-12-01 | 2024-02-01 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
CA3096713A1 (en) | 2018-04-19 | 2019-10-24 | The Regents Of The University Of California | Compositions and methods for gene editing |
AU2021209699A1 (en) | 2020-01-22 | 2022-07-21 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing tau expression |
WO2022009987A1 (en) * | 2020-07-09 | 2022-01-13 | Modalis Therapeutics Corporation | Method for treating alzheimer's disease by targeting mapt gene |
CA3197644A1 (en) * | 2020-10-02 | 2022-04-07 | Sangamo Therapeutics, Inc. | Novel zinc finger protein transcription factors for repressing alpha-synuclein expression |
WO2023184107A1 (en) * | 2022-03-28 | 2023-10-05 | Huigene Therapeutics Co., Ltd. | Crispr-cas13 system for treating mecp2-associated diseases |
WO2023184108A1 (en) * | 2022-03-28 | 2023-10-05 | Huigene Therapeutics Co., Ltd. | Crispr-cas13 system for treating ube3a-associated diseases |
WO2024032679A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
WO2024032677A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
WO2024032678A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9428756B2 (en) * | 2006-08-11 | 2016-08-30 | Dow Agrosciences Llc | Zinc finger nuclease-mediated homologous recombination |
WO2011139349A1 (en) * | 2010-05-03 | 2011-11-10 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
EP2820159B1 (en) * | 2012-02-29 | 2019-10-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treating huntington's disease |
WO2017197141A2 (en) * | 2016-05-13 | 2017-11-16 | Sangamo Therapeutics, Inc. | Targeted treatment of androgenic alopecia |
WO2018039471A2 (en) * | 2016-08-25 | 2018-03-01 | Trustees Of Boston University | Synthetic transcriptional and epigenetic regulators based on engineered, orthogonal zinc finger proteins |
US10960085B2 (en) * | 2016-09-07 | 2021-03-30 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
US11371023B2 (en) * | 2016-11-22 | 2022-06-28 | Wisconsin Alumni Research Foundation | Artificial transcription factors and uses thereof |
AU2017367722B2 (en) * | 2016-12-01 | 2024-02-01 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
-
2019
- 2019-10-02 JP JP2021518086A patent/JP2022504075A/ja active Pending
- 2019-10-02 AU AU2019354743A patent/AU2019354743A1/en active Pending
- 2019-10-02 WO PCT/US2019/054347 patent/WO2020072684A1/en unknown
- 2019-10-02 US US16/591,445 patent/US20200109406A1/en active Pending
- 2019-10-02 CN CN201980077887.5A patent/CN113195002A/zh active Pending
- 2019-10-02 EP EP19869126.3A patent/EP3861130A4/en active Pending
- 2019-10-02 SG SG11202103314QA patent/SG11202103314QA/en unknown
- 2019-10-02 CA CA3115158A patent/CA3115158A1/en active Pending
- 2019-10-02 KR KR1020217013170A patent/KR20210069692A/ko active Search and Examination
-
2021
- 2021-03-31 IL IL281950A patent/IL281950A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019354743A1 (en) | 2021-05-06 |
KR20210069692A (ko) | 2021-06-11 |
CA3115158A1 (en) | 2020-04-09 |
SG11202103314QA (en) | 2021-04-29 |
EP3861130A4 (en) | 2022-08-03 |
WO2020072684A1 (en) | 2020-04-09 |
CN113195002A (zh) | 2021-07-30 |
IL281950A (en) | 2021-05-31 |
EP3861130A1 (en) | 2021-08-11 |
US20200109406A1 (en) | 2020-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7381476B2 (ja) | 希少疾患の処置のための方法および組成物 | |
JP2022504075A (ja) | 操作された遺伝子モジュレーター | |
US11110154B2 (en) | Methods and compositions for treating Huntington's Disease | |
US20230270774A1 (en) | Tau modulators and methods and compositions for delivery thereof | |
US20200101133A1 (en) | Methods and compositions for modulation of tau proteins | |
US20220064237A1 (en) | Htt repressors and uses thereof | |
RU2789459C2 (ru) | Модуляторы тау и способы и композиции для их доставки |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240228 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |